Saturday, April 9, 2022

Axios Pro Rata: 💼 JOBS Act legacy

Plus: IPO data | Saturday, April 09, 2022
 
Axios Open in app View in browser
 
Presented By Emergent BioSolutions
 
Axios Pro Rata
By Kia Kokalitcheva · Apr 09, 2022

Happy Saturday!

  • 🚨 Reminder: Feel free to send me tips or comments by replying to this email or on Twitter @imkialikethecar.

Today's newsletter is 948 words, a 3.5-minute read.

 
 
1 big thing: 10 years after the JOBS Act became reality
Photo illustration of the New York Stock Exchange.

Photo Illustration: Shoshana Gordon/Axios; Photo: Daniel Acker/Bloomberg via Getty Images

 

The JOBS Act celebrated its 10th birthday on Tuesday. Signed into law by President Obama to great bipartisan fanfare, it was intended to jump-start an increase in IPO filings, but a decade later has ultimately yielded mixed results.

Why it matters: The legislation was hailed at the time by its supporters as an antidote to some of the Sarbanes-Oxley Act's onerous auditing and reporting requirements and the failure of the U.S. Securities and Exchange Commission to make it easier for companies to go public.

Flashback: The law that was eventually named the Jumpstart Our Business Startups (JOBS) Act was born out of Washington's efforts to counter the drop-off in IPOs in the years following the dot-com bust.

  • "If you're a startup and you take money from early stage investors, there are really only two ways to return that capital to the investors… selling or going public," Latham & Watkins partner Joel Trotter said on Tuesday during a roundtable hosted by the House Financial Services Committee, which convened participants who worked on the law. "We thought the balance had tilted too far toward M&A."
  • Some of the legislation's shepherds also touted public companies as significant creators of jobs, adding to the argument that the U.S. should get more businesses to go public.

Yes, but: "What determines a company going public: the market... and the stage of a company and the availability of private capital for funding," University of Florida professor Jay Ritter, who studies IPOs, tells Axios. "All of these things are independent from tweaks in regulation."

  • The JOBS Act also made it easier for companies to not go public sooner, he adds, for instance by increasing the maximum number of shareholders of record a company can have before it has to register to go public.
  • The boom in available private capital in the decade since the law passed also affected IPO decisions. "If it wasn't there, there would probably be fewer startups, and there would be more hasty exits," Ritter said.

But, but, but: The JOBS Act did include some productive provisions — namely allowing emerging growth companies (EGCs) to confidentially file a draft of their IPO prospectus for feedback from the SEC, and the ability to "test the waters" with institutional investors, says Ritter.

  • While in office, SEC Chairman Jay Clayton extended those benefits to all companies in a bid to further stimulate IPOs.

Moreover: Proponents of the legislation also tout the high share of EGCs among IPOs in the years since, hinting that the JOBS Act's on-ramp and lower compliance burden were effective tools.

  • Since 2013, 93% of U.S. IPOs were completed by EGCs, per a report from the House Financial Services Committee.

What we're watching: Whether the SPAC mania and cryptocurrency boom will cool regulators' interest in new rules that are in the spirit of the JOBS Act.

Share on Facebook Tweet this Story Post to LinkedIn Email this Story
 
 
2. One boom, one whimper
Illustration of a hand putting down coins.

Illustration: Aïda Amer/Axios

 

Along with IPOs, the JOBS Act included provisions that dealt with other forms of fundraising — like crowdfunding and private capital raises.

Why it matters: While crowdfunding (and its cousin, Regulation A+ offerings) didn't become the blockbuster hit their architects hoped, the newfound ability for startups to fundraise through "general solicitation" made it possible for platforms like AngelList to flourish.

Crowdfunding and Regulation A+:

  • Crowdfunding offerings in the first three years after the provision took effect in 2015 were well below the then-limit of $1.07 million, despite more companies using it, per SEC staff reports. (2020 was a record year, however.)
  • And while the number of offerings under the updated Regulation A+ went up, the capital raised in aggregate and the number of offerings have paled in comparison to traditional IPOs, suggesting it remains a more niche fundraising mechanism.

Private placements:

  • The JOBS Act lifted the ban on general solicitation for companies raising capital through a Regulation D exemption — that is, the usual startup-style raising of venture capital.
  • The only caveat was that the company would have to ensure that it was raising only from "accredited investors," which excludes checks from friends and family that don't meet accreditation requirements. Until 2020, those were income- and wealth-based, though certain professional investors can now meet them thanks to their jobs.
  • Most importantly, Title II made it possible for AngelList (and later, other marketplaces) to flourish. The company, which wasn't charging fees before the JOBS Act, and thus avoided legal troubles, became the go-to network for accredited angel investors to meet startups looking for funding.
  • A report from the House Committee on Financial Services also notes that sites like AngelList have contributed to an increase in funding for startups led by underrepresented founders.

The bottom line: The JOBS Act being a bit of a hodge-podge of various measures has not surprisingly led to some provisions being more successful than others.

Share on Facebook Tweet this Story Post to LinkedIn Email this Story
 
 
3. EGCs waste no time
Adapted from a Latham & Watkins report; Note: Year one data is as of April 5, 2013, and year two data is as of March 31, 2014; Table: Axios Visuals

Emerging growth companies (EGCs) wasted no time in taking advantage of the provisions in the JOBS Act, which took effect the day President Obama signed the bill into law.

Share on Facebook Tweet this Story Post to LinkedIn Email this Story
 
 

A message from Emergent BioSolutions

We Go to create a world that's prepared and protected
 
 

Emergent maintains a critical role in the ongoing opioid crisis. We're developing emergency rescue medications that can help reverse an opioid overdose. It's just one of the ways we defend people from things we hope will never happen.

Learn more about Emergent's protections.

 
 
📚 Due Diligence
Share on Facebook Tweet this Story Post to LinkedIn Email this Story
 
 
🧩 Trivia

Some of the last few years' biggest IPO headliners — despite having well-known brands and generating constant press coverage — were in fact qualifying "emerging growth companies" with annual revenue below $1.07 billion.

  • Question: Name one such company? (Answer at the bottom.)
Share on Facebook Tweet this Story Post to LinkedIn Email this Story
 
 
🧮 Final Numbers
Data: U.S. House Financial Services Committee; Note: 'Before' data refers to 2008-2012 and 'After' data refers to 2013-2021; Chart: Simran Parwani/Axios
  • Midsize IPOs saw the biggest growth post-JOBS Act.
Share on Facebook Tweet this Story Post to LinkedIn Email this Story
 
 

A message from Emergent BioSolutions

We Go to create a world that's prepared and protected
 
 

Emergent maintains a critical role in the ongoing opioid crisis. We're developing emergency rescue medications that can help reverse an opioid overdose. It's just one of the ways we defend people from things we hope will never happen.

Learn more about Emergent's protections.

 

🙏 Thanks for reading! See you on Monday for Pro Rata's weekday programming, and please ask your friends, colleagues and IPO filers to sign up.

Trivia answer: There are many well-known EGCs — Snap, Lyft and even WeWork (when it initially tried to go public), to name a few.

Axios Pro
Go deeper with Axios Pro: Deals, featuring hyper-relevant news and analysis across PE, VC and M&A.
 

Axios thanks our partners for supporting our newsletters. If you're interested in advertising, learn more here.
Sponsorship has no influence on editorial content.

Axios, 3100 Clarendon B‌lvd, Suite 1300, Arlington VA 22201
 
You received this email because you signed up for newsletters from Axios.
Change your preferences or unsubscribe here.
 
Was this email forwarded to you?
Sign up now to get Axios in your inbox.
 

Follow Axios on social media:

Axios on Facebook Axios on Twitter Axios on Instagram
 
 
                                             

No comments:

Post a Comment

Buy Alert: Top 5 AI Stocks to Buy Now

EMAIL VERSION #1 / AT Leadgen / Elon Musk's Secret AI Plan Unsubscribe ...